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High molecular-weight phthalates, such as diisononyl phthalate (DINP), and diisodecyl phthalate (DIDP), are widely used as
plasticizers in the manufacturing of polymers and consumer products. Human biological monitoring studies have employed the
metabolites of DINP and DIDP as biomarkers to assess human exposure. In this review, we summarize and analyze publicly
available scientiﬁc data on chemistry, metabolism, and excretion kinetics, of DINP and DIDP, to identify speciﬁc and sensitive
metabolites. Human biological monitoring data on DINP and DIDP are scrutinised to assess the suitability of these metabolites as
biomarkers of exposure. Results from studies carried out in animals and humans indicate that phthalates are metabolised rapidly
and do not bioaccmulate. During Phase-I metabolism, ester hydrolysis of DINP and DIDP leads to the formation of hydrolytic
monoesters. These primary metabolites undergo further oxidation reactions to produce secondary metabolites. Hence, the levels
of secondary metabolites of DINP and DIDP in urine are found to be always higher than the primary metabolites. Results from
human biological monitoring studies have shown that the secondary metabolites of DINP and DIDP in urine were detected in
almost all tested samples, while the primary metabolites were detected in only about 10% of the samples. This indicates that the
secondary metabolites are very sensitive biomarkers of DINP/DIDP exposure while primary metabolites are not. The NHANES
data indicate that the median concentrations of MCIOP and MCINP (secondary metabolites of DINP and DIDP, resp.) at a
population level are about 5.1μg/L and 2.7μg/L, respectively. Moreover, the available biological monitoring data suggest that
infants/children are exposed to higher levels of phthalates than adults.
1.Introduction
Phthalates are a group of synthetic chemicals that are dialkyl
or aryl/alkyl diesters of phthalic acid. Since the 1920s,
phthalates have been widely used in the chemical industry
in the manufacturing of polymers and a variety of consumer
products. Currently, more than 12 billion lbs of phthalates
areproducedannuallyworldwide[1].Highmolecular-weight
phthalates, such as DINP and DIDP, have been mainly
used as plasticizers in polymer manufacturing. Phthalate
plasticizers are used to impart ﬂexibility and durability to
PVC polymers. Considerable amounts of DINP and DIDP
are found in several industrial and consumer products
such as construction materials, electrical wires and cables,
automotive parts, clothing, and furniture [2–4]. As phtha-
lates are not chemically bound to the polymers, there is
a concern that they could leach out from the polymer
matrix during usage [5]. Stringent government regulations
in North America and Europe on the use of DEHP in
consumer products have resulted in its substitution with
other less toxic phthalates, notably DINP and DIDP [1].
This has prompted their inclusion in several national-
level human biological monitoring surveys [6–10]. Earlier
human biological monitoring studies have used MINP, the
monoester metabolite of DINP, as a urinary biomarker to
assesspopulationexposuretoDINP[7,11,12].Thesestudies
have shown that the concentration of MINP in human urine
is very low and often below the limit of detection of the
analytical method employed. Researchers have speculated
that such low concentration of MINP could be due to low
human exposure to DINP or could indicate that MINP is not
a sensitive biomarker for DINP exposure [7, 12]. Subsequent2 Journal of Environmental and Public Health
research on human metabolism and excretion of DINP has
shown that most of the MINP formed is oxidized further
to secondary metabolites prior to excretion [13, 14]. These
results highlight the importance of choosing sensitive and
speciﬁc biomarkers to assess human exposure to phthalates.
In this review, we summarize publicly available scientiﬁc
data on chemistry, metabolism, and excretion kinetics, of
DINP and DIDP. Major metabolites of DINP and DIDP that
may be useful as exposure biomarkers in human biological
monitoring studies are identiﬁed. Human biological mon-
itoring data from around the world are analyzed to assess
the suitability of speciﬁc metabolites of DINP and DIDP
as exposure biomarkers for future biological monitoring
studies.
2. Chemistry
Unlike DEHP, DINP and DIDP are mixtures of structurally
similar chemical compounds. Two diﬀerent compositions of
DINP, namely, DINP-1 (CAS no. 68515-48-0) and DINP-
2 (CAS no. 28553-12-0), are commercially available and
are used interchangeably in industrial applications. Another
DINP mixture, DINP-3 (CAS no. 28553-12-0), was previ-
ously in commerce but is now discontinued [15]. Like DINP,
DIDP is also commercially available in two compositions
(CAS nos. 68515-49-1 and 26761-40-0) which are fully
interchangeable.
2.1. Production and Composition of DINP. Commercially
available DINP is a complex mixture of diesters of o-phthalic
acid containing C8–C10 (C9 rich) alkyl side chains. In
the plasticizer industry, the term “iso” (as in di“iso”nonyl
phthalate) refers to the “mixture of isomers” rather than
the structural classiﬁcation based on IUPAC nomenclature.
DINP has an average molecular formula of C26H42O4
and molecular weight of 420.6g/mol. Although DINP-1
and DINP-2 share these general characteristics, they are
manufactured via two distinct chemical processes and hence
their ﬁnal chemical compositions diﬀer considerably. DINP-
1 is manufactured using the “polygas” process (as reported
in [16]). In this process, propylene and butanes (n-butene
and isobutene) undergo oligomerization to produce octene.
Oxonation and hydrogenation of octene produces isononyl
alcohols, mainly dimethyl heptanol-1, which is reacted with
phthalic anhydride to obtain DINP-1. The DINP-2 manufac-
turingprocessutilisesn-buteneasthestartingmaterial.Here,
n-butene is subjected to dimerization to yield isooctene.
Oxonation and hydrogenation of isooctene primarily results
in the formation of methyloctanols and dimethyl heptanols
that are esteriﬁed with phthalic anhydride to yield DINP-2.
Exxon Mobil Chemicals and BASF are the major produc-
ers of DINP plasticizers in the world. Both chemical manu-
facturers have studied the purity and the main constituents
of DINP. In terms of ester content, the purity of DINP-1
and DINP-2 are >99.5% [17]. However, the GC-MS analysis
of pure DINP samples yielded multiple chromatographic
peaks, indicating the presence of several structural isomers
[18]. Koch et al. [19] analyzed isononyl alcohol (INA), used
in the production of DINP-1 (INA-1) and DINP-2 (INA-2)
using GC-MS, and found that INA-1 contains at least
15 isomers, while INA-2 contains >35 isomers. Moreover,
they estimated that 4-methyloctanol-1 is the major isomer,
constituting about 20% of INA-2 and 8.7% of INA-1. As
INA-1 and INA-2 form the side chain of the ﬁnal DINP-1
and DINP-2 mixtures, respectively, the above observations
suggest that the 4-methyloctanol side chain dominates the
DINP-1 and DINP-2 mixtures.
2.2. Production and Composition of DIDP. The two commer-
cially available DIDP formulations are synthesised from the
same starting materials, namely, propylene and butenes. The
starting materials are subjected to oligomerization, followed
by distillation to isolate C9 rich alkenes (nonenes). The
alkenes undergo oxonation and hydrogenation processes to
form linear and branched chain (C9–C11) alcohols, rich
in C10 isomers. The alcohols undergo esteriﬁcation with
phthalic anhydride at high temperature (140◦C–250◦C) in
the presence of a catalyst to form DIDP (as reported in [20]).
Diﬀerences in the oxonation and esteriﬁcation processes
lead to the formation of two diﬀerent DIDP formulations.
However, for all practical purposes, these two formulations
are completely interchangeable.
Like DINP, DIDP is a complex substance that consists of
several structural isomers. DIDP has an average molecular
weight of 446.68g/mol and is represented by the molecular
formula C28H46O4. Based on 1H-NMR analysis of isodecyl
alcohol used in the manufacturing of DIDP, the commercial
DIDP formulations are estimated to contain about 70–80%
of dimethyl octanol side chains and the remaining 20–30%
is made of methyl nonanols and trimethyl heptanols (<10%)
([21]a sr e p o r t e di n[ 20]). The GC-MS analysis of the DIDP
sample extracted from water showed the presence of at least
29 distinct chromatographic peaks. Rastogi [18]a n a l y z e d
pure DIDP and DINP samples using GC-MS and found
that both samples have multiple chromatographic peaks.
Although DIDP chromatographic peaks eluted at slightly
higher GC retention times, both DIDP and DINP showed
overlapping chromatographic peaks suggesting the presence
of common constituents.
3. Metabolism of DINP andDIDP
Due to the ubiquitous nature of phthalates, it has proven
diﬃcult to avoid external phthalate contamination during
processing and analysis of environmental and biological
samples.Moreover,asdiscussedbelow,phthalatesarerapidly
metabolized in humans. Therefore, in human biological
monitoring studies, phthalate metabolites (as opposed to
the parent phthalates) are measured as biomarkers of
exposure [6, 9, 22]. Hence, an understanding of human
metabolism and excretion kinetics of phthalates is crucial
for identifying metabolites that are speciﬁc and sensitive
to phthalate exposure. The urinary metabolic proﬁles of
DINP/DIDP are complicated due to several factors. As stated
earlier, the commercial DINP/DIDP formulation contains
several structural isomers, and hence, exposure to such a
mixture would result in the formation of many structurally
similar metabolites. It is diﬃcult to separate and identifyJournal of Environmental and Public Health 3
individual isomeric metabolites, even with the state-of-the-
art analytical techniques. To date, the identity of only some
of these metabolites in human urine samples has been
conﬁrmed using high-performance liquid chromatography-
tandem mass spectrometric technique [19]. In addition to
this complexity, although DINP and DIDP predominantly
contain compounds with C9 and C10 side chains, respec-
tively, compounds with longer or shorter side chains are
also detected in considerable amounts in their commercial
formulations. For example, commercial DINP mixtures
(DINP-1 and DINP-2) are known to contain DIDP (C10
side chain) and DNOP (C8 side chain) [16, 19]. This implies
that exposure to DINP could produce DNOP and DIDP
metabolites in addition to the metabolites that are speciﬁc
to DINP.
Studies on phthalate metabolism, conducted in rodents,
aswellasinhumans,haveshownthatphthalatesaremetabo-
lized very quickly and do not bioaccumulate [13, 14, 23, 24].
Despite diﬀerences in their physical and chemical properties,
the metabolism of DINP/DIDP is very similar to that of
DEHP [25, 26]. The proposed Phase-I metabolic pathway
for DIDP and DINP in humans involves a preliminary ester
hydrolysis step through which the hydrolytic monoesters
(primary metabolites) are formed (Figure 1)[ 23]. The
hydrolytic monoester undergoes oxidative metabolism via
the ω-oxidation (oxidation at the terminal carbon atom of
the side chain) or (ω-1) oxidation (oxidation at penultimate
carbon atom of the side chain) pathway to form secondary
metabolites with hydroxy-, oxo-, and carboxy-functional
groups[19].Metabolismofthesecondarymetabolitesispos-
sible and tertiary metabolites were also detected (Figure 1)
[13, 14]. All these metabolites could also undergo Phase-
II metabolism by conjugation with glucoronic acid and
sulphonic acid to form respective conjugates before their
elimination via urine.
Silva et al. [14] identiﬁed several primary and secondary
metabolites of DINP in rat urine using HPLC(ESI)-MS/MS
technique. The presence of MIDP, MNOP, and MCPP,
in addition to MINP, was conﬁrmed by comparing the
chromatographic retention time and the mass fragmen-
tation pattern of the metabolites with that of authentic
standards. Using full-scan negative ion ESI mass spectra,
they also identiﬁed several secondary metabolites of DINP:
MCIOP (ω-oxidation product of DINP; Figure 1), as well as
MHINP and MOINP ((ω-1) oxidation products; Figure 1).
However, isomeric metabolites were not well resolved and
their identiﬁcation was based entirely on the mass spectral
fragmentation patterns and speciﬁc MS/MS transitions. The
authors also observed that the concentrations of secondary
metabolites (such as MHINP and MOINP) of DINP were
considerably higher than MINP. In addition to the DINP
metabolites,secondarymetabolitesofDNOP(e.g.,MCIHPP,
MHIOP, MOIOP) and DIDP (e.g., MCINP, MHIDP) were
also identiﬁed in this study based on speciﬁc MS/MS
transitions. Thus, as stated in the previous paragraph, the
interpretation of DINP metabolism is complicated by the
presence of not only several structural isomers of DINP, but
also by the presence of other phthalates such as DNOP and
DIDP.
Kato et al. [13] followed the metabolism of commercial
DIDP mixture in rats after oral administration of DIDP
at a dose of 300mg/kg-body. Urine samples were collected
one day before dosing and three subsequent days imme-
diately after dosing and analyzed for DIDP metabolites.
The analytical method involved an enzymatic deconjuga-
tion step, followed by sample cleanup using online solid-
phase extraction, and analysis using HPLC(ESI)-MS/MS
technique. The secondary metabolites, such as MCINP and
MHIDP, were the major metabolites (see Figure 1); the
monoestermetabolite,MIDP,wasonlypresentattracelevels.
BesidesDIDPmetabolites,speciﬁcmetabolitesofDINP(e.g.,
MHINP) and DIUDP (e.g., MHIUDP) were also detected.
The concentrations of the majority of metabolites in urine
returned to baseline levels within 48 hours after dosing,
suggesting a rapid clearance. Although the half-lives of
individualmetaboliteswerenotreported,theauthorssuggest
a half-life of about 14h for all the metabolites.
Thus, studies on the metabolism of DINP and DIDP
in rats suggest that these compounds are metabolised very
rapidly. The primary metabolites of DINP/DIDP undergo
extensive oxidation reactions during Phase-I to produce
secondary metabolites. The DINP/DIDP urinary metabolic
proﬁles suggest that the secondary metabolites dominate
in urine while monoester metabolites (MINP and MIDP)
are only minor metabolites. Metabolic and excretion studies
carried out in humans (discussed in the next section)
indicate that DINP/DIDP metabolic pathways in rats and
humans are very similar.
4.ExcretionofDINP andDIDP
Absorption, distribution, metabolism, and excretion studies
conducted in rats show that after oral administration, the
absorption of DINP/DIDP via gastrointestinal (GI) tract
is very rapid, while their dermal absorption appears to be
very minimal (<5%) [16, 24]. Once absorbed, DINP/DIDP
predominantly distributes in blood, liver, and kidney. Initial
ester hydrolysis of DINP/DIDP to their corresponding
monoesters (MINP/MIDP) appears to happen in the GI
tract; further oxidation of MINP/MIDP, to respective sec-
ondary metabolites (e.g., MHINP, and MOINP/MHIDP, and
MOIDP), takes place in the liver [24]. The urinary metabolic
proﬁles of DINP/DIDP are dominated by the secondary
metabolites, and often no measurable concentrations of pri-
mary metabolites (MINP/MIDP) or the parent compounds
(DINP/DINP) are detected [24]. On the other hand, in feces,
most of the DINP/DIDP is excreted as parent compounds
andaverysmallamountisexcretedassecondarymetabolites
[16, 24].
Koch and Angerer [27] studied the urinary elimina-
tion kinetics of D4-ring labelled DINP-2 in humans by
administering 98.2mg of the substance orally (1.27mg/kg-
body weight) to an adult volunteer. The excretion of
monoesters, as well as oxidized metabolites of D4-DINP,
was analyzed in 22 urine samples collected during a span
of 48 hours postdosing. The primary metabolites (MINP)
and the secondary metabolites with hydroxy-, oxo-, and
carboxy-functional groups were identiﬁed using respective4 Journal of Environmental and Public Health
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Figure 1:ProposedmetabolictransformationofDINPandDIDPbasedonstudiesconductedinrodentsandhumans[6].Forsimplicity,the
linearsidechainsaredepictedinphthalatestructuresinthisﬁgure.Legends:DIDP:diisodecylphthalate;DINP:Diisononylphthalate;MIDP:
monoisodecyl phthalate; MINP: monoisononyl phthalate; MHIDP: monohydroxy isodecyl phthalate; MCINP: monocarboxy isononyl
phthalate; MCIOP: monocarboxy isooctyl phthalate; MHINP: monohydroxy isononyl phthalate; MOIDP: monooxoisodecyl phthalate;
MCIHPP: monocarboxy isoheptyl phthalate; MCIHXP: monocarboxy isohexyl phthalate; MOINP: monooxoisononyl phthalate; MCIPEP:
monocarboxy isopentyl phthalate; MCIBP: monocarboxy isobutyl phthalate; MCPP: monocarboxy propyl phthalate; MCEP: monocarboxy
ethyl phthalate [13, 14, 22, 23].
D4-labelled standards. Elimination kinetics of D4-DINP
in humans shows a biphasic pattern—a fast elimination
phase (within 24hr postdosing) followed by a relatively
slow elimination phase after 24hr. The elimination half-
lives estimated for MINP and oxidized metabolites were
3hr and 5hr in the ﬁrst phase, and 12hr and 18hr
in the second phase, respectively. In the ﬁrst elimination
phase, the concentrations of hydroxy-metabolites were the
highest, followed by the oxo-metabolites, and carboxy-
metabolites. In the second elimination phase (>24hr post
dosing), the concentrations of carboxy-metabolites were
higher than all other metabolites. The concentration of
MINP was lower than the secondary metabolites at all
sampling times. Moreover, almost all MINP was eliminated
within24hrpostdosing,whilehydroxy-andoxo-metabolites
were detected up to 48hr postdosing. Carboxy-metabolites
weredetectedevenafter48hr.Thefractionalexcretionfactor,
deﬁned as the molar ratio of the total amount of metabolite
excreted to the applied dose of the parent compound, for
MINP, MHINP, MOINP, and MCIOP were 0.02, 0.2, 0.1,
and 0.1, respectively. These estimates also show that about
40% of the ingested DINP is excreted as hydroxy-, oxo-, and
carboxy-metabolites within 48h after dosing.
Recently, a similar study was carried out in 20 adult
human volunteers (ten males and ten females) to assess the
variability in DINP elimination kinetics due to diﬀerences in
theingestedDINPdoseandgender[23].Understrictclinical
control, these volunteers were administered two doses of
D4-labelled DINP-2: 0.121mg/kg body weight (high dose;
7.3mg overall) and 0.012mg/kg body weight (low dose;Journal of Environmental and Public Health 5
0.78mg overall). These doses are about ten to hundred times
lower than the dose (1.27mg/kg body weight; 98.2mg) used
inthepreviousstudy[27].Urinesampleswerecollectedfrom
the participants for up to 48hr postdosing, at an interval of
fourhoursbetweensamples.Allurinesampleswereanalyzed
forprimary aswellassecondarymetabolites. Morethan90%
of each metabolite was excreted within 24 hours postdosing,
suggesting rapid clearance. The concentrations of secondary
metabolites (MHINP and MOINP) were higher than MINP
in the urine samples collected during all time periods.
The estimated elimination half-lives of the metabolites were
between four and eight hours, which are slightly lower
than the values reported in the previous study [27]. The
fractional excretion factors for MINP, MHINP, MOINP, and
MCIOP estimated in this study were 0.03, 0.12, 0.06, and
0.07, respectively. Two-way ANOVA analysis was performed
to assess the eﬀect of dose and gender on the excretion of
DINP metabolites. The results show that gender did not
have any statistically signiﬁcant eﬀect on the excretion of
the DINP metabolites. The administered dose of DINP had
a statistically signiﬁcant eﬀect on the excretion of MINP;
however, such dose eﬀects were not observed for other
metabolites.Despitethefactthat,inthisstudy,thevolunteers
ingested about ten to hundred times lower dose of DINP
than the single volunteer in the Koch and Angerer study,
the overall metabolic proﬁle and the excretion kinetics of the
targeted metabolites in these two studies were very similar.
The longer half-lives of secondary metabolites of DINP/
DIDP together with their higher fractional excretion factors
shown in the excretion studies indicate that the secondary
metabolites are more sensitive biomarkers of phthalate
exposure than the primary metabolites.
5.Biological Monitoringof DINP andDIDP
5.1. Exposure Biomarkers for Phthalates: General Considera-
tions. Due to the widespread use of DIDP, DINP, and other
phthalates in consumer products, humans are exposed to
these compounds on a daily basis [5, 28, 29]. In the last
decade, several studies have been carried out to assess the
exposure of the general population to phthalates, to identify
vulnerable populations, and to develop mitigation measures
to reduce exposure [2, 13–16, 18, 20].
Human biological monitoring can be broadly deﬁned as
the measurement of a chemical, its metabolites, and/or its
reaction products, in human body ﬂuids and other tissues
[30, 31]. The choice of biological matrix depends on several
factors that include the study design, the characteristics
of the chemical (e.g., physical and chemical properties,
metabolism, excretion kinetics, etc.), and the availability of
validated analytical methods. Traditionally, the concentra-
tions of persistent pollutants (e.g., dioxins and furans) are
measured in whole blood and blood components (such as
plasma and serum), while nonpersistent pollutants (e.g.,
phthalates and environmental phenols) are measured in
urine samples [30, 32]. Other biological matrices that have
been considered for biological monitoring include saliva,
breast milk, amniotic ﬂuid, and seminal ﬂuid [31, 33, 34].
Urinecollectionproceduresareverysimple,noninvasive,
andstraightforward.Moreover,largevolumesofurinecanbe
obtained withvery little discomfortto the study participants.
These attributes are desirable in large biological monitoring
studies. However, as mentioned before, the detection of trace
levels of phthalate diesters in urine samples is complicated
due to its ubiquitous presence and rapid metabolism [35].
Hence, for biomonitoring purposes, phthalate metabolites
a r ep r o p o s e da sr e l i a b l eb i o m a r k e r so fe x p o s u r e .
An ideal phthalate exposure biomarker would be a very
stable metabolite with a relatively long half-life (t1/2) in the
biologicaltissue/matrix (e.g.,plasma,serum,urine) inwhich
it is measured. The metabolite should also be stable during
sampling, sample processing, and analysis. Furthermore,
the metabolite should be speciﬁc to the parent phthalate
of interest. Several high-molecular-weight phthalate diesters
are known to have common metabolites (e.g., DINP,
DNOP, and DIDP; Figure 1). Although analysis of such
metabolites would be useful to establish phthalate exposure
in general, detailed information on the metabolism and
excretion kinetics of individual parent phthalates is required
to assess their contribution to the measured concentrations
of these metabolites. Finally, major metabolites of the parent
phthalateswouldserveasgoodbiomarkers,astheirdetection
frequency would be higher.
5.2. Review of Human Biological Monitoring Data. The
availabilityofbiologicalmonitoringdataonDINPandDIDP
is very limited. Concentrations of DINP and DIDP metabo-
lites measured in biological monitoring studies conducted
around the world are summarized in Table 1. Most of these
studies were either carried out in a speciﬁc population (e.g.,
pregnant women, children) or with a relatively small sample
size. Nevertheless, the metabolite concentrations reported
in these studies are very similar. In general, the observed
urinary concentrations of phthalate metabolites in biological
monitoring studies are inﬂuenced by several factors, in
addition to exposure. Some of these factors include the study
design, age, time of sample collection (morning, afternoon
and evening), nature of the samples (spot urine versus
24h urine), and the analytical method used [30, 36, 37].
Hence, the data interpretation should be carried out with
caution, as the observed diﬀerences in the concentrations
of the metabolites may not necessarily reﬂect diﬀerences in
exposure patterns.
Silva et al. [22] analyzed the concentrations of MINP,
MHINP, MOINP, and MCIOP in 129 adult urine samples to
assess the suitability of these metabolites as biomarkers for
exposure assessments. MHIOP was detected in all the urine
samples while MCIOP and MOINP were detected in 97%
and 87% of the samples, respectively. On the other hand,
the MINP concentration was below the detection limit
(<0.36ng/mL) in all the tested samples. They also noted that
while MOINP was excreted in human urine predominantly
as a glucuronide conjugate, MCIOP was excreted mostly
as unconjugated (free form). The MHINP was excreted
either as a conjugate or as a free compound. Recently,
Calafat et al. [6] reported concentrations of MCIOP and
MCINP in the United States general population (>6y e a r s6 Journal of Environmental and Public Health
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of age; 2005-2006 survey). These two metabolites were
detected in about 90% of the tested samples at a median
concentration of 5.10ng/mL and 2.7ng/mL, respectively.
However, the monoester metabolite, MINP, was detected in
only about 12% of the tested samples. In addition, the MINP
concentrations in >80% of the samples analyzed during
earlier U.S. national surveys (NHANES: 1999-2000, 2001-
2002,2003-2004)werebelowthelimitofdetection(0.8μg/L)
[11]. In Canada, MINP was measured in urine of the general
population (n = 3235) under the Canadian Health Measures
Survey (CHMS; cycle-1; 2007–2009). Preliminary results
from this survey suggest that MINP levels in >99% of the
samples are below the analytical detection limit (0.4μg/L)
[Saravanabhavan, unpublished data]. Even in the samples
where MINP was found, the levels were very low (range:
<LOD-3.34ng/mL). This is consistent with other biological
monitoring studies done around the world [22, 38–40].
Moreover, only very few biological monitoring studies have
reported the concentrations of DIDP metabolites in human
urine (Table 1). From studies in which both DINP and
DIDP metabolites were measured, one could observe that
the concentrations of secondary metabolites of DIDP were
relatively lower compared to those of DINP metabolites [9,
32, 41]. The median urinary concentration of MCINP in the
spot urine samples from a pregnant women cohort in Spain
(2.8μg/L) [41] is very similar to the median concentration
of MCINP (2.7μg/L) reported in the U.S. general population
[41]. The median concentrations of MCINP from German
studies (children: 1.3μg/L [9]; adults: 0.7μg/L [32]) were
lower than the above data. Thus, the data from biological
monitoringstudiesaswellastheresultsfromthemetabolism
and excretion studies discussed in the previous sections
collectively suggest that MINP is not a sensitive exposure
biomarker of DINP. A similar conclusion may be drawn
aboutMIDP(monoestermetaboliteofDIDP),asbothDINP
and DIDP metabolism follow similar biochemical pathways.
It is desirable to measure more than one secondary
metabolite of DINP/DIDP in human biological monitoring
studies to assess human exposure. However, due to logistic
and economic reasons, it is not often feasible to measure
multiple metabolites for each parent phthalate in large
biological monitoring studies. The data in Table 1 suggest
that, in general, the concentrations of secondary metabolites
of DINP/DIDP are higher than the monoester metabolites.
Among the secondary metabolites of DINP, the median
concentrations of hydroxy-metabolites (MHINP), formed
via the (ω-1) oxidation pathway, are the highest, followed
by the carboxy- and oxo-metabolites (MCIOP and MOINP)
(Table 1). In the case of DIDP, the concentrations of the
carboxy-metabolites, formed via the ω-oxidation pathway,
are the highest. Previous biological monitoring studies have
shown that the concentrations of primary and secondary
metabolites (e.g., MINP and MHINP) and the concentra-
tions among the secondary metabolites (e.g., MHINP and
MOINP; MHINP and MCIOP) in urine samples are highly
correlated [6, 22], suggesting that these metabolites origi-
nated from the same parent compound (Figure 1). Hence,
measurement of at least one secondary metabolite arising
from the (ω-1) and ω oxidation pathways is recommended
to assess human exposure to DINP/DIDP.
A few scientiﬁc studies have assessed the intra- and inter-
individual variability in urinary metabolite concentrations.
Fromme et al. [42] analyzed the concentrations of phthalate
m e t a b o l i t e si n2 7m e na n d2 3w o m e n ,a g e db e t w e e n1 4
and 60 years, living in Germany. To assess the daily varia-
tions, phthalate metabolites were measured in the morning
urine samples collected from the participants over eight
consecutive days. Several phthalate metabolites, including
two secondary metabolites of DINP, namely, MHINP and
MOINP, were tested. They observed a signiﬁcant day-to-day
variation in the metabolite concentrations. The interclass
correlation coeﬃcient (ICC), deﬁned as the ratio of the
inter-individual variance to the total variance, for MHINP
and MOINP, were 0.31 and 0.33, respectively. Such low ICC
values suggest the presence of considerable intra-individual
variability in the metabolite concentrations. Hence, the
authors suggest that the phthalate concentrations measured
using single urine samples may not be adequate for exposure
assessment.
For logistic reasons, national-level biological monitoring
programs prefer collecting spot urine samples from study
participants which are then analyzed for environmental
chemicals including phthalate metabolites [6, 10, 43]. How-
ever, rapid clearance of DINP/DIDP metabolites in humans
suggests that the metabolite concentrations in spot urine
samples would reﬂect only recent exposure. Nevertheless,
due to the analysis of a large number of samples in national-
level biomonitoring studies, such as NHANES and CHMS,
we speculate that the eﬀects of iner-day and intra-day
variations on the concentrations of phthalates in spot urine
samples, measured at a population level, would be minimal.
Wittassek et al. [8] studied trends in the concentration
of phthalate metabolites in young adults (mean age 24 years)
residing in Germany by analysing biobanked urine samples
collected from 1988 to 2003. They found that the concentra-
tions of DINP metabolites (MHINP and MOINP) increased
continually from 1988 to 2003, while the concentrations of
DEHP metabolites decreased over the same time period.
The authors suggest that this might reﬂect the fact that,
in Europe, DEHP is being substituted by DINP in plastic
manufacturing.
The results from NHANES (2005-2006) show that the
urinary concentrations of MCIOP and MCINP have an
inverserelationshipwiththeageofthestudyparticipants;the
concentrations of these metabolites were signiﬁcantly higher
in children compared to adults [6]. Similar results were
reported from the GerES IV study conducted in Germany in
which phthalate metabolites were analyzed in urine samples
collected from 599 children, aged between 3 and 14 years
[10]. The concentrations of secondary metabolites of DINP
were signiﬁcantly higher in toddlers (3–5 years) compared
to children in higher age groups (6–8 years; 9–11 years; 12–
14 years). Lin et al. [38] measured the concentrations of
MHINP, MOINP, and MCIOP in spot urine samples from
pregnant women, toddlers (2-3 years), and young children
(5-6 years). The concentrations of all these metabolites were
higher in the toddlers and children than in the pregnantJournal of Environmental and Public Health 9
women. Casas et al. [41] measured the concentrations of
MCIOP and MCINP in spot urine samples from pregnant
women and boys (4 years old) from ﬁve diﬀerent cohorts.
They found that the median concentration of these analytes
were higher in the children than in the pregnant women.
In this study, the boys and pregnant women cohorts were
obtained from diﬀerent geographical regions in Spain, thus
the regional diﬀerences, in addition to age, may have
contributed to the observed increase in concentrations
of phthalate metabolites in boys. In a children’s cohort
study conducted in Germany, Koch et al. [9]m e a s u r e d
the concentrations of secondary metabolites of DINP and
DIDP, in addition to other phthalate metabolites, in urine
samples from 111 children, aged between 5 and 6 years.
In general, the concentrations of secondary metabolites of
DINP/DIDP were lower than the secondary metabolites of
DEHP. However, the estimated mean total daily intake values
for DEHP, DINP, and DIDP were 4.5, 2.4, and 0.3μg/kg
body weight/day, respectively, suggesting that the exposure
to DINP/DIDP is signiﬁcant and can increase the total
phthalate body burden among children. All these biological
monitoring data suggest that infants and young children are
exposed to higher levels of DINP and DIDP than adults.
Previous exposure assessment studies have also sug-
gested that infants could have high phthalate exposure
[15, 16, 20]. PVC-based materials are commonly used in
the manufacturing of toys designed for infants and young
children. As phthalates are not chemically bound to PVC, the
DINP/DIDP could migrate to the saliva during sucking and
chewing of toys by infants, thereby increasing their exposure.
The magnitude of DINP exposure in infants assessed by
diﬀerent researchers diﬀers widely. This may be due to
diﬀerences in the assumptions made on the use of toys,
duration of mouthing, and the phthalate migration rates,
risk assessment modeling, and so forth. As per European
Union’s risk assessment report, the estimated DINP expo-
sure through the use of consumer products in infants (6
months to 3 years; assuming mouthing of toys) is higher
(249.9μg/kgbodyweight/day;95thpercentile)thaninadults
(10.8μg/kg body weight/day; 95th percentile). In infants,
mouthing of toys alone contributed to roughly 200μg/kg
body weight/day of DINP exposure [16]. In 1998, Health
Canada carried out a risk assessment on DINP in vinyl
children’sproducts[44].Basedonthescientiﬁcdataavailable
at that time, the DINP exposure in infants (3 months to 1
year)wasestimatedtorangefrom5μg/kgbodyweight/dayto
458μg/kg body weight/day. However, the Dutch Consensus
Group (RIVM) [45] estimated the DINP daily oral exposure
of <26μg/kg body weight/day (95th percentile) in infants
aged 3 months to 6 months through the use of teethers.
The United States Consumer Products Safety Commission
(CPSC) [46] has estimated DINP exposures in infants due
to mouthing of toys as 94.3μg/kg body weight/day (3 to 12
months; 95th percentile) and 7.6μg/kg body weight/day (12
to 26 months; 95th percentile). In a recent reassessment,
Babich et al. [47] estimated even lower DINP exposure
levels in infants due to the use of PVC-based toys. Using
the information on the migration rates and the mouthing
duration from the CPSC observational study, the authors
applied probabilistic methods to estimate DINP exposure.
The daily DINP exposure in infants (at 95th percentile) was
estimatedtobe0.44μg/kgbodyweight/day(3to11months),
0.53μg/kgbodyweight/day(12to23months)and0.56μg/kg
body weight/day (24 to 36 months). In the case of DIDP,
the European Union’s risk assessment report estimated the
exposure to be 226.5μg/kg body weight/day in infants
(assuming mouthing of toys) of which the contribution
from mouthing of toys alone is 200μg/kg body weight/day.
The total exposure estimate of DIDP in children and adults
(>3y e a r s )i s5 . 8 μg/kg body weight/day. Thus, both the
biological monitoring studies and exposure assessments
have identiﬁed infants and young children as vulnerable
population subgroups for DINP/DIDP exposure.
6. Conclusion
DINP and DIDP are widely used as plasticizers in polymer
manufacturing. Due to their relatively low toxicity, DINP
a n dD I D Ph a v eb e e ns e e na ss u i t a b l er e p l a c e m e n t sf o rm o r e
toxic phthalates (such as DEHP) in the manufacturing of
consumer products. As a result, there is an interest to
assess the body burden of these phthalates occurring from
nonoccupational exposure [22, 32]. Although the human
biological monitoring data on DINP and DIDP are currently
very limited, the available data suggest widespread human
exposure to these compounds.
Several phthalate metabolites have been proposed as
biomarkers to quantify phthalate exposure in biological
monitoring studies. DINP, DIDP, and other high-molecular
weight phthalates metabolize diﬀerently compared to low-
molecular-weight phthalates, such as diethyl phthalate. The
hydrolytic monoesters are the major metabolites of low-
molecular-weight phthalates; however, the monoesters of
high-molecular-weightphthalatesundergofurtheroxidation
to form secondary metabolites. Hence, monoester metabo-
lites (MINP and MIDP) of DINP and DIDP are not
detected frequently in human urine. The hydroxy- and keto-
metabolites of DINP/DIDP are unique and can be formed
only by the oxidation of respective monoester metabolites.
Duetotheirhighspeciﬁcity,thesemetabolitesareveryuseful
in biological monitoring studies to assess human exposure
to DINP/DIDP. On the other hand, the carboxy-metabolites,
suchasMCIOP,canbeformedbytheoxidationofmorethan
one parent phthalate, suggesting poor speciﬁcity. However,
one could speculate that the major proportion of any given
carboxy-metabolite is derived from the monoester phthalate
that is closer to it in the oxidation pathway. For example,
the presence of MCIOP in human urine is a better indicator
of exposure to DINP, although this compound may also be
formed from DIDP. Overall, the secondary metabolites of
DINP/DIDP are appropriate urinary biomarkers to assess
human exposure to DINP and DIDP. The concentrations
of secondary metabolites in infants and children are higher
than in adults, which might indicate high exposure levels in
infants/children. Moreover, the exposure estimates based on
the concentrations of monoester metabolites of DINP and
DIDP are likely to underestimate human exposure to these
compounds.10 Journal of Environmental and Public Health
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MOIDP: Monooxoisodecyl phthalate
MCINP: Monocarboxy isononyl phthalate
MHIUDP: Monohydroxy isoundecyl phthalate
LOD: Limit of detection
NHANES: National Health and Nutrition Examination
Survey
GerES: German Environmental Survey
PVC: Polyvinyl chloride
GC-MS: Gas chromatography-mass spectrometry
HPLC: High-performance liquid chromatography
NMR: Nuclear magnetic resonance spectroscopy
ESI: Electrospray ionisation.
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